A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

This study is testing a new drug called HS-10502 (a PARP inhibitor) in patients with advanced solid tumors that have a specific type of DNA repair gene mutation called HRR (homologous recombination repair). Such mutations make cancer cells unable to fix their own DNA properly, which certain drugs can exploit. **You may be eligible if...** - You are between 18 and 75 years old - You have an advanced solid tumor with an HRR gene mutation (or HRD-positive) that has not responded to, or is not eligible for, standard treatments - Eligible cancer types include ovarian cancer (HRD positive), HER2-negative breast cancer, pancreatic cancer, prostate cancer, colorectal cancer, and others with HRR mutations - Your general health is good (ECOG 0–1) - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - You have previously been treated with a PARP inhibitor - You have serious heart, liver, kidney, or blood count problems - You are pregnant or breastfeeding - You have had recent major surgery or radiation Talk to your doctor to see if this trial is right for you.